

Peyman Banooni M.D.

Curriculum vitae

PROFESSIONAL EXPERIENCE

PEYMAN BANOONI MD (PBMD) Beverly Hills	07/2003 – Present
PEYMAN BANOONI MEDICAL GROUP, INC. Huntington Park Downtown Los Angeles	09/2011 – 02/2017
UNITED CLINICAL RESEARCH 6208 Seville Ave. Huntington Park, CA 90255	12/2016 – 2021
MATRIX CLINICAL RESEARCH 1919 W 7 th St, Los Angeles, CA 90057	02/2018 - Present
ANGELES COMMUNITY HEALTH CENTER CEO	02/2017-PRESENT

EDUCATION

Fellow American College of Obstetrics and Gynecology, 2006
Cedars-Sinai Medical Center, OB/GYN residency, Completion June, 2003
University of California, San Diego, M.D. degree, June 1999
University of California, Los Angeles, Bachelors of Science in Biology,
Summa Cum Laude, College Honors, June 1995

HONORS & ACADEMIC DISTINCTIONS

2023	Secretary Department of OBGYN, Cedars Sinai Medical Center PIC Committee
2017-present	Cedars Sinai Medical Center Peer Review Committee Member
2012-present	Director Gynecology Center of Excellence at La Peer Health Systems
2010-2012	Voted member Cedars Sinai Medical Center Medical Executive Committee
2010-2014	Medical Expert for Medical Board of California
2008-2012	Cedars Sinai Medical Center Performance Improvement Committee
2008-	Member of Cedars Sinai Center of Excellence for Minimally Invasive Gynecologic Surgery
2007-2008	Cedars Sinai Medical Center Performance Improvement Committee Member Medical Leadership Conference Cedars Sinai Alumni Association- Secretary UCLA Medical Students Core Clerkship Teaching Award
2004-2006	Cedars Sinai Alumni Association- Treasurer IAMA Board of Directors
2003.	Society of Laparoendoscopic Surgeons Outstanding Laparoendoscopic Resident Chief Resident, Cedars-Sinai Medical Center Resident Research presentation: "Eight-Year experience with management of monoamniotic twins"

AMA Physician Recognition Award
 Cedars-Sinai Award of recognition
 PCX (Patient care expert) advisory committee
 Wyeth ACOG Conference Resident Reporter

- 1998 Organizer for second year medical student elective: "Pathophysiologic Correlates to the Physical Examination"
 Achievement Rewards for College Scientists (ARCS) Foundation Scholarship
 Mackenzie Scholarship
 Hillyer Scholarship
- 1997 Speaker at American Federation for Medical Research Annual Western Student Medical Research Forum, "Minimal Access Surgery for Staging of Pancreatic Cancer," Carmel, California.
 Achievement Rewards for College Scientists (ARCS) Foundation Scholarship

HONORS & ACADEMIC DISTINCTIONS

- 1996 Speaker at the First Annual Conference of the Committee on Iranian Jewish Oral History, "Jews in Iran (1800 to present)," January 13-15, 1996, Simon Wiesenthal Center, Los Angeles, California
 NIH- Children's Hospital of Los Angeles/USC Summer Oncology Fellowship
 California Academy of Family Physicians Family Medicine Preceptorship Program
 Betty Ford Center at Eisenhower Summer Institute for Medical Students Internship
 1996 McGraw Hill Award for Achievement and Contribution
 Achievement Rewards for College Scientists (ARCS) Foundation Scholarship
- 1992-95 Biology Departmental Honors
 Dean's Honors List for 8 quarters at UCLA
 UCLA Medical Center Auxiliary Volunteer Scholarship
 UCLA Presidential Undergraduate Fellowship

RESEARCH

- 2022** GlaxoSmithKline (GSK)
PRINCIPAL INVESTIGATOR Los Angeles, CA
 A phase IIIB, open label, non-randomized, controlled, multi-country study to evaluate safety, reactogenicity and immunogenicity of the repeat vaccination with 120 µg dose of RSV maternal vaccine during subsequent pregnancy in healthy maternal participants 18-49 years of age.
- 2022** Sorrento Therapeutics, Inc.
PRINCIPAL INVESTIGATOR Los Angeles, CA
 Validation: NP RT-PCR vs. COVISTIX
- 2021** Sorrento Therapeutics, Inc.
PRINCIPAL INVESTIGATOR Los Angeles, CA
 Validation of Nasal COVISTIX vs. Nasal RT-PCR
- 2021** Pfizer
SUB INVESTIGATOR Los Angeles, CA
 A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2

RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER

2021	Abbott Molecular, Inc. PRINCIPAL INVESTIGATOR Alinity m HR HPV Specimen Collection Study from Women Referred to Colposcopy	Los Angeles, CA
2021	Duke Clinical Research Institute PRINCIPAL INVESTIGATOR ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications	Los Angeles, CA
2021	University of Pittsburgh PRINCIPAL INVESTIGATOR COVID-19 Outpatient Thrombosis Prevention Trial within ACTIV-4: A multicenter adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis	Los Angeles, CA
2021	Abbott Diagnostics Scarborough, Inc. PRINCIPAL INVESTIGATOR RealTime SARS-CoV-2 Specimen Collection	Los Angeles, CA
2021	Evoform PRINCIPAL INVESTIGATOR Phase 3 double-blind placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhea infection	Los Angeles, CA
2020	Pfizer PRINCIPAL INVESTIGATOR A PHASE 3, RANDOMIZED, DOUBLE BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY	Los Angeles, CA
2020	Abbott Diagnostics Scarborough, Inc. PRINCIPAL INVESTIGATOR 2012601: Clinical Evaluation of the Investigational ID NOWTM COVID-19 Assay	Los Angeles, CA
2020	Merck Sharp & Dohme Corp. PRINCIPAL INVESTIGATOR A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger	Los Angeles, CA
2020	GlaxoSmithKline (GSK) PRINCIPAL INVESTIGATOR A Phase III, randomized, double-blind, placebo-controlled multi- country study to demonstrate efficacy of a single dose of RSV MAT (RSVPreF3) vaccine (GSK3888550A), administered IM to	Los Angeles, CA

healthy pregnant women 18 to 45 years of age, for prevention of RSV LRTI in their infants up to 6 months of age

2020	Sanofi Pasteur, Inc. SUB INVESTIGATOR	Gardena, CA
	Phase I/II, randomized, observer-blind, placebo-controlled, multi-center, dose-finding study to evaluate the safety, immunogenicity, infectivity, and vaccine virus shedding after 1 and 2 administrations of the recombinant live attenuated Respiratory Syncytial Virus (RSV) ΔNS2/Δ1313/I1314L vaccine in infants and toddlers 6 to 18 months of age in the United States and Latin America	
2020	Sanofi Pasteur, Inc. PRINCIPAL INVESTIGATOR	Los Angeles, CA
	Phase II Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants	
2020	Sanofi Pasteur, Inc. SUB INVESTIGATOR	Gardena, CA
	Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers	
2020	Pfizer SUB INVESTIGATOR	Gardena, CA
	A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS	
2020	Pfizer PRINCIPAL INVESTIGATOR	Los Angeles, CA
	A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS	
2019	ObsEva S.A. PRINCIPAL INVESTIGATOR	Los Angeles, CA
	A Phase 3 multicenter, randomized, double-blind, placebo- controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis- associated pain.	
2019	Laboratoire HRA Pharma PRINCIPAL INVESTIGATOR	Los Angeles, CA
	Adherence with Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use (ACCESS)	
2019	GlaxoSmithKline (GSK) PRINCIPAL INVESTIGATOR	Los Angeles, CA
	A Phase II, randomized, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational	

RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers

- | | | |
|------|--|-----------------|
| 2019 | <p>Pfizer
 PRINCIPAL INVESTIGATOR
 A Phase 2b, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (RSV) vaccine in pregnant women 18 through 49 years of age and their infants</p> | Los Angeles, CA |
| 2018 | <p>Iterum Therapeutics International Limited
 PRINCIPAL INVESTIGATOR
 A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract infections in adult women.</p> | Los Angeles, CA |
| 2018 | <p>Sanofi Pasteur, Inc.
 PRINCIPAL INVESTIGATOR
 A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the United States</p> | Los Angeles, CA |
| 2018 | <p>Mycovia Pharmaceuticals, Inc
 PRINCIPAL INVESTIGATOR
 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis</p> | Los Angeles, CA |
| 2018 | <p>Evoform
 PRINCIPAL INVESTIGATOR
 Phase 2B/3 double-blinded placebo-controlled efficacy trial of AMPHORA gel for the prevention of acquisition of urogenital Chlamydia trachomatis infection</p> | Los Angeles, CA |
| 2018 | <p>Bayer
 PRINCIPAL INVESTIGATOR <i>An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure®) or laparoscopic tubal sterilization</i></p> | Los Angeles, CA |
| 2018 | <p>Bayer
 PRINCIPAL INVESTIGATOR
 <i>Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of treatment effect on heavy menstrual bleeding</i></p> | Los Angeles, CA |
| 2018 | <p>Roche
 PRINCIPAL INVESTIGATOR
 <i>Clinical performance of cobas® HPV for use on the cobas® 6800/8800 Systems using cervical samples collected in PreservCyt® for identification of high-grade cervical disease (cX8-HPV-435); and ¹_{SEP} Clinical performance of CIntec® PLUS Cytology on the VENTANA BenchMark® ULTRA</i></p> | Los Angeles, CA |

instrument for identification of high-grade cervical disease when used as a reflex test in high-risk HPV-positive women (D032425)

- 2017** **Besins Healthcare (BHR PHARMA, LLC.)** Los Angeles, CA
PRINCIPAL INVESTIGATOR
A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women with BI-RADS Breast Density Categories C or D (BHR-700-301)
- 2017** **Building Blocks Nutritional** Los Angeles, CA
SUB-INVESTIGATOR
BBN-IF-001 Growth and Safety Study of an Infant Formula for Healthy Term Infants
- 2017** **ObsEva S.A.** Los Angeles, CA
PRINCIPAL INVESTIGATOR ^[1]_{SEP}
A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.
- 2017** **ObsEva S.A.** Los Angeles, CA
PRINCIPAL INVESTIGATOR
A Phase 3, multicentre, randomized, double-blind, placebo- controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add- back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
- 2017** **Novavax Inc.** Los Angeles, CA
PRINCIPAL INVESTIGATOR
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in their Infants. ^[1]_{SEP}
- 2016** **ObsEva S.A.** Los Angeles, CA
SUB-INVESTIGATOR
A Phase 3 study of OBE2109 in subjects with heavy menstrual bleeding associated with uterine fibroids, multicentre, randomized, double-blind, placebo- controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add- back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Dr. Frias as Principal Investigator.
- 2016** **Radius Pharmaceuticals, Inc.** Los Angeles, CA
SUB-INVESTIGATOR
*Protocol VMRAD1901-203: "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms"
Dr. Patrick Clarke as Principal Investigator.*
- 2015** **REPROS** Los Angeles, CA
SUB-INVESTIGATOR
A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal

Women with Symptomatic Uterine Fibroids" Protocol Number ZPU-304; with Dr. Hazan of Axis Clinical Trials as Principal Investigator

- 2015** **WYETH** Los Angeles, CA
SUB-INVESTIGATOR
 A Double-Blind, Randomized, Placebo and Active-controlled Efficacy and Safety study of XXXX. Drug For Prevention of endometrial Hyperplasia And Prevention of Osteoporosis in Postmenopausal Women
- 2012** **BERLEX** Los Angeles, CA
SUB-INVESTIGATOR
 A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled, 7 Cycle Duration (196 days), Phase 3 Study of Oral XXXX Tablets for the Treatment of Dysfunctional Uterine Bleeding
- 2012** **LUITPOLD PHARMACEUTICALS, INC** Los Angeles, CA
INVESTIGATOR
 Comparison of the Safety of a Unique Intravenous Iron Preparation (XXX) Versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary To Heavy Uterine Bleeding
- 1992** Department of Pathology- Dr. Anthony Verity, Chief of Department of Pathology, University of California Los Angeles, School of Medicine
- 1995** Minimal access surgery for staging of pancreatic cancer, Dr. Dilip Parekh, Department of Surgery, University of Southern California, School of Medicine
- 1995** HIV tropism and Alternate vectors for gene therapy, Dr. Irvin Chen, Director of UCLA AIDS Institute, Department of Microbiology and Hematology & Oncology- University of California Los Angeles, School of Medicine
- 1998** Demographics, risk factors, prenatal diagnosis, and short and long term outcomes of fetuses diagnosed with Gatoschisis, Dr. Thomas Kelly, Department of Reproductive Medicine, University of California San Diego, School of Medicine
- 2003** Eight year experience with management of monoamniotic twins, Dr. Neil Silverman, Dept of Ob/Gyn, Cedars-Sinai Medical Center

PUBLICATIONS

- Banooni P, Graupe M, Silverman N. Eight Year Experience with Management of Monoamniotic Twins. Paper in preparation.
- Banooni P, Rickman L, Ward D. Potts Puffy Tumor Related to Use of Intranasal Amphetamine. *JAMA*. Vol 283(10): 1293, March 8, 2000.
- Planelles V, Bachelier F, Haislip A, Banooni P, and Chen I. Fate of Human Immunodeficiency Virus Type I Provirus in Infected Cells: a role for *vpr*. *Journal of Virology*, Sept. 1995, pp.5883-5889.
- Banooni P, Simnegar S. Terua: The History of Contemporary Iranian Jews, *History of Jews in Iran (1500 to present)*, Chapter 2: pp. 13-43, Publishings of Center for Iranian Jewish Oral History, Los Angeles, California, October 1996.

ABSTRACTS

- Banooni P, Graupe M, Silverman N. Eight Year Experience with Management of Monoamniotic Twins. Poster presentation. ACOG Annual Clinical Meeting. New Orleans. April, 2003.
- Banooni P, Visaya L, and Parek D. Minimal Access Surgery for Staging of Pancreatic Cancer. Abstract presented at American Federation for Medical Research Annual Western Student Medical Research Forum. Carmel, California. February, 1997.
- Planelles V, Bachelerie F, Haislip A, Banooni P, and Chen I. The Fate of HIV-1 Proviral DNA in Infected Cells. Abstract presented at First West Coast Retrovirus Meeting. Irvine, California. October, 1994.
- Planelles V, Bachelerie F, Haislip A, Banooni P, and Chen I. The Fate of HIV-1 Proviral DNA in Infected Cells: A Novel Role for *vpr*. Abstract presented at Annual UCLA AIDS Symposium. Santa Monica, California. November, 1994.

CERTIFICATIONS

- Good Clinical Practice (GCP)
- International Air Transport Association (IATA)

PRIOR MEMBERSHIPS

- The Society of Laproendoscopic Surgeons
- North American Menopause Society
- Cedars Sinai Alumni Association

HOSPITAL ADMITTING PRIVELEGES

- Cedars Sinai Medical Center